Overall 5-year continuous complete remission (CCR) for regimen B was 72 ± 2% (s.e.) and for regimen C, 73 ± 2% (P = 0.72 by log-rank analysis). Significant differences between treatments for CCR, testicular, CNS relapses overall or with regard to phenotype (pre-B vs early pre-B), gender, or race were not detected. During intensification, regimen C had significantly more bacterial infections (P = 0.05) and days spent in the hospital (P Ͻ 0.001) compared with regimen B, while regimen B had significantly more allergic reactions (P Ͻ 0.0001). No significant differences in CCR were noted between patients with pre-B and early pre-B ALL (P = 0.22 stratified by risk group and treatment). This study was unable to detect statistical difference between asparaginase (regimen B) and cytarabine (regimen C) during the intensification phase of therapy in children with B-lineage acute lymphocytic leukemia. Leukemia (2000) 14, 1570-1576.
Introduction
Event-free survival (EFS) of children with B-precursor acute lymphocytic leukemia (ALL) has improved dramatically during the last three decades. Currently, 70 to 80% of children achieve long-term disease-free survival. A major component of this success has been the addition of an intensification phase of therapy given after a patient is in remission.
1,2 A variety of chemotherapeutic agents including antimetabolites, anthracyclines, alkylating agents and the epipodophyllotoxins has been used during intensification. There have been a few reports of intensification regimens that have excluded alkylating agents, anthracyclines and the epipodophyllotoxins. Investigators from Roswell Park Memorial Institute, 3, 4 and the Cancer and Acute Leukemia Group B, 5, 6 described the use of intermediate-dose methotrexate (IDMTX) as intensification treatment in childhood ALL. The Pediatric Oncology Group (POG) performed a pilot study using overlapping 24-h infusions of the anti-metabolite methotrexate (MTX) and cytarabine (AraC) for intensification therapy. 7 At 4 years, the Kaplan-Meier estimate of event-free survival (EFS) was 71 ± 7% for 57 standard prognosis patients and 53 ± 8% for Correspondence: MB Harris, Tomorrows Children's Institute, Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601, USA; Fax: 201-487-7340 49 high-risk patients. Clavell and colleagues 8 reported that a regimen including intensive weekly intramuscular (i.m.) asparaginase (ASP) therapy for 24 weeks produced an EFS of 86 ± 4% in children with standard prognosis and 71 ± 4% in children with poor prognosis ALL. The high-risk group received doxorubicin and higher doses of prednisone during continuation therapy. Graubner et al 9 used an intensification regimen of IDMTX followed 24 h later with ASP and reported at 54 months a CCR of 86 ± 6% for standard prognosis and 60 ± 9% for high-risk patients. In the latter two reports, other drugs and the definition of standard prognosis and poor prognosis differed from the POG protocol.
Based on these data the Pediatric Oncology Group (POG) designed a randomized trial (POG 8602) to investigate the effectiveness of antimetabolite-based intensification regimens in the treatment of patients with standard prognosis or poor prognosis B-precursor ALL. The objectives of this study were to compare the EFS of children with pre-B or early pre-B ALL treated with intensification regimens that used IDMTX alone or in combination with ASP or AraC and to analyze the toxicity of these antimetabolite-based intensification regimens. Two reports 10, 11 consider other therapeutic objectives of POG protocol 8602. The current report, which is the main paper of POG study 8602, compares the efficacy of ASP to AraC of all concurrently standard prognosis and poor prognosis patients with early pre-B and pre-B ALL.
Patients and methods
POG 8602 opened in February 1986 with regimens A, C and D and in May 1987, regimen B opened (Figure 1 ). This report covers concurrently randomized patients to regimens B and C. From May 1987 to January 1991, 1354 eligible patients with standard or poor prognosis pre-B (cytoplasmic immunoglobulin positive) or early pre-B ALL were registered on POG 8602 (Table 1 ). All patients had Ͼ25% lymphoblasts in their diagnostic bone marrow aspiration. The lymphoblasts were myeloperoxidase or Sudan black and non-specific esterase negative, and lacked T cell-associated markers and surface immunoglobulin. Standard prognosis was defined as age 1-10.99 years and WBC Ͻ10.0 ϫ 10 9 /l, or age 3-5.99 years and WBC Ͻ100.0 ϫ 10 9 /l. High-risk was defined as age 1-10.99 years and WBC у10 ϫ 10 9 /l, or age 3-5.99 years and WBC у100 ϫ 10 9 /l, or age у11 years, or a mediastinal mass. Patients whose blasts contained the Philadelphia chromosome [t(9;22)], or who had central nervous system disease at diagnosis (blasts present on cytospin examination of cerebrospinal fluid in which the WBC was у5 cells/l), or who were morphologically FAB L 1 or L 2 with surface immunoglobulin or positivity (ie mature B cell immunophenotype) were considered high risk. These patients were non-randomly assigned The four regimens used in POG 8602. AraC, cytarabine; MTX, methotrexate; TIT, triple intrathecal medication; VCR, vincristine; IDMTX, intermediate-dose methotrexate; PDN, prednisone; 6-MP, mercaptopurine. (Table 1) . Ninety-eight previously reported patients 10 were treated on regimen D and are not included in the present analysis. Similarly, 163 standard prognosis patients with early pre-B ALL randomized to regimen A 11 are also not included in the present analysis. Additionally, nine patients refused randomization, one physician refused a patient's randomization, and one patient thought to have early pre-B ALL was determined to have pre-B ALL on later review. Induction ( Figure 2) leucovorin was given 24 h after the lumbar puncture. The dose of calcium leucovorin was the same as the intrathecal methotrexate dose. 6-Mercaptopurine (6-MP), 75 mg/m 2 p.o., was given on days 29-43 to all patients in complete remission (CR) at day 29. CR required fewer than 5% lymphoblasts in the day 29 bone marrow aspirate, a hemoglobin у11 g/dl, an absolute neutrophil count у1.5 ϫ 10 9 /l, a platelet count у100.0 ϫ 10 9 /l, cerebrospinal fluid free of blasts, and a normal physical examination and performance status.
Of the 1323 patients who entered remission, 1051 eligible SP, standard prognosis, PP, poor prognosis. a These estimates stratified by natural weight amongst those achieving a CR: 557:353:411 for SP early pre-B: PP early pre-B: pre-B respectively, to adjust for the actual unnatural weights assigned to these treatments due to the varying eligibility to other regimens. A simple pooled curve would have been heavily biased for over representing pre-B, who were randomized only to B vs C, and under representing SP early pre-B who were randomized to regimens A and D, in addition to B and C. Two-sided log-rank P values for treatment comparisons stratified for risk group within phenotype, and risk group and phenotype overall: early pre-B SP (P = 0.86); early pre-B PP (P = 0.27); early pre-B overall (P = 0.32); pre-B overall (P = 0.079); and overall (P = 0.72). Continuous complete remission (CCR) refers to the time from achievement of a complete remission to the last clinical contact or failure from any cause (excluding induction failure). This outcome measure was converted to event-free survival (EFS) by multiplying the CCR by the rate of remission induction.
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Patient characteristics
While the AlinC14 (POG 8602) data played a major role in the construction of the National Cancer Institute age/WBC Consensus Risk Groups definition, 12 these designations could not be used in the current analysis of this trial due to the complex stratification that affected the overall number of treatments used within strata. The NCI Consensus Risk Groups define standard prognosis patients as children Ͻ10.00 years of age with a WBC Ͻ50.0 ϫ 10 9 /l. Within early pre-B standard prognosis patients, 92% were NCI Consensus-Risk Standard; within pre-B standard prognosis patients, 87% were NCI Consensus-Risk Standard; within early pre-B poor prognosis patients, 43% were NCI Consensus-Risk Standard; and within pre-B poor prognosis patients, 44% were NCI Consensus-Risk Standard. Median age and quartiles at diagnosis were 4.4, 3.0 and 7.8 years, while median WBC and quartiles were 9, 4 and 29 respectively.
Five hundred and seventy-four males and 477 females were randomized on to regimens B or C. The racial background of the patients were 80% Caucasian, 8% African-American, 7% Hispanic and 5% other or unknown.
Statistical considerations
The trial was stratified by phenotype (early pre-B vs pre-B) and by risk group (standard vs poor prognosis). Patients achieving a complete remission were randomized on day 43. The major objective was the overall comparison of the durations of continuous complete remission (CCR) stratified for risk group and phenotype. Secondarily, we wished to compare the treatments within the following categories: early pre-B (standard prognosis), early pre-B (poor prognosis), and early pre-B (stratified for POG age/WBC risk group), and pre-B (stratified for POG age/WBC risk group). Due to the small numbers, there was no objective to compare treatments within pre-B prognostic subgroups, although we do provide the comparisons for interested readers. Also secondarily, we provide comparisons of targeted toxicities and days hospitalized during intensification, the period where the two treatment regimens were different.
Actuarial survival analysis was used for all analyses other than toxicity comparisons, which employed the chi-square test and days hospitalized, which employed the Wilcoxon test. Actuarial comparisons were conducted by the log-rank test, 13 stratified where indicated. Descriptive measures of 4-7 year outcome were constructed by the Kaplan-Meier method, 14 with standard errors of Peto and co-workers. 13 Because of the unusual nature of the design, where the randomization was amongst four regimens in early pre-B standard prognosis (three regimens when regimen D closed), three regimens for early pre-B poor prognosis (two regimens when regimen D closed) and two regimens for pre-B, construction of the overall results were stratified by the natural weights amongst these three subgroups. Simple pooling of the data would have resulted in significantly biased estimates of the overall outcome, since the design led to over representation of pre-B and under representation of early pre-B, standard prognosis patients. Follow-up was excellent with less than 4% of patients censored prior to the end of their fourth year post randomization. Assuming proportional hazards, the study had at least 80% power to detect a hazard ratio (ratio of instantaneous risks regimen B:regimen C) of 1.38 or higher or one of 0.73 or lower. 
Results
Outcome Tables 2 and 3 provide the primary results of the paper, using POG risk categories, as designed in the protocol. The overall 5-year CCR for regimen B was 72 ± 2% (s.e.) and for regimen C, 73 ± 2%. The overall treatment comparison for CCR is P = 0.72, by the stratified log-rank test. At 5 years, the estimated difference in CCR rates is 1.0%, favoring regimen C, with 95% confidence limits from a 5.4% advantage for regimen B to a 7.4% advantage for regimen C. Although this is an inconclusive result, we can reasonably conclude that no major advantage for either treatment exists. There were no significant differences in outcome by phenotype, or by risk group within phenotype. A log-rank comparison of prognosis between early pre-B and pre-B with respect to CCR, stratified by risk group and treatment, revealed no significant difference (P = 0.22). Table 4 provides an accounting of the reasons for failure, by treatment, phenotype, and risk group. 29.8% of all patients recurred. In line with expectations, the distribution of the failures is as follows: 71% involved the bone marrow, 16% CNS only, and 13% (of the male failures) the testes. We analyzed the treatment differences within gender, and within race (African-American, Caucasian and Hispanic). There were no significant treatment differences within any of these subsets (data not shown).
Table 4
Reasons for failure Patients  174  157  114  117  155  154  91  89  534  517  Males  98  79  60  59  91  95  49  43  298  276  Failures  32  30  30  25  55  68  42  31  159  154  BM  25  20  22  13  37  49  33  23  117  105  CNS   a   4  7  5  7  8  1 0  6  4  2 3  2 8  Testes  3  2  2  2  5  6  3  2  13 Secondary neoplasm was large cell non-Hodgkin's lymphoma. f Other failures were for unknown cause (1), fatal accident (1), off study for coma and dying of unknown cause (1). Table 5 describes non-allergic grades 3 and 4 toxicities for regimens B and C during the intensification phase of treatment. Patients on regimen C had significantly more leukopenic and infectious episodes as well as an increase in emesis. These patients also spent more days in the hospital compared to patients on regimen B. The latter was due not only to the increased toxicity of the IDMTX + AraC infusion but also to the longer period required to complete the infusion of IDMTX and AraC (36 h) compared to IDMTX alone (24 h).
Standard prognosis Poor prognosis Total
EPB EPB PB PB EPB EPB PB PB Regimen B C B C B C B C B C
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Toxicity
Allergic reactions were far more frequent during the intensification phase of regimen B, a result directly attributable to the use of ASP in regimen B (Table 6 ). Patients who experienced allergic reactions to E. coli asparaginase were switched to Erwinia asparaginase.
Therapy during maintenance was identical for regimens B and C and the toxicity profiles (data not shown) were similar. Grade 3 and 4 neutropenia was almost universal with patients experiencing an occasional episode of this complication at some point during the maintenance phase of treatment. Other common toxicities included infections (bacterial and viral), transaminase elevations, and gastrointestinal symptoms. CNS events occurred in less than 5% of patients during maintenance.
Discussion
Although more than 70% of children with ALL will be longterm survivors there remains a significant survival advantage for children with standard prognosis ALL compared to those with high-risk disease. 1, [7] [8] [9] [10] [16] [17] [18] The Pediatric Oncology Group in 1986 opened a randomized study to evaluate if the addition of either intensive ASP or AraC to IDMTX intensification would enhance the survival of children with ALL. The study intentionally used only antimetabolite therapy in order to decrease the long-term effects that are associated with ther- (18) (19) (20) (21) (22) (23) (24) (25) Ͻ0.001
Toxicity grading: infection − 3 = treatment required, 4 = life-threatening; nausea/vomiting -3 = vomiting 1-4/day, 4 = hydration required; stomatitis -3 = ulcers, unable to eat, 4 = massive ulcer; CNS -3 = seizures, psychosis, 4 = comatose. a Median. b Quartiles. apy that utilizes anthracyclines, alkylating agents or epipodophyllotoxins.
We have previously reported the results of children with early pre-B ALL who were standard or poor prognosis and who were randomized to receive intensification with IDMTX plus AraC every 3 weeks or every 12 weeks. 10 EFS for patients with standard prognosis ALL were 79% and 85% and for poor prognosis patients were 66% and 61% using the upfront and spread-out regimens. These differences were not significant. Recently, POG reported on the results of 727 standard prognosis patients with early pre-B ALL treated with either IDMTX alone, or with IDMTX and ASP or with MTX and AraC. 11 The EFS for each of the regimens was approximately 80%. In this report, we have demonstrated that patients with ALL who were treated on POG 8602 had an overall CCR of approximately 70% at 5 years with the use of either IDMTX + ASP or IDMTX + AraC during the intensification phase of therapy. Patients with POG criteria for standard prognosis fared better, with an approximate 80% 5-year CCR, compared to patients with high-risk whose 5-year CCR was approximately 60%. Therefore, one interpretation of the data from POG 8602 is that neither ASP nor AraC improves the CCR rate that is achieved with intensification therapy with IDMTX alone. However, the design of POG 8602 did not randomize patients with pre-B ALL or high-risk early pre-B ALL to regimen A, and therefore, we do not know how these patients would have fared with MTX intensification alone. These conclusions are the same if the NCI Consensus Risk Groups 12 are used instead of the POG risk groups.
Clavell et al 8 demonstrated that intensive ASP during an intensification phase of therapy improved the EFS of both standard prognosis and poor prognosis patients. We were unable to demonstrate the superiority of ASP + IDMTX to AraC + IDMTX in this or our previous report. 11 The incidence of allergic reactions to ASP was 61.8% in POG 8602, considerably higher than the 10% noted in the studies originating from the Dana-Farber Cancer Institute. 8, 16 In our previous report, we speculated that the higher incidence of allergic reactions during intensification could have resulted from an anamnestic antibody response induced by the prior use of ASP during induction. 11 Clavell et al did not use ASP until the intensification phase of treatment. We speculated that these allergic reactions reflected the presence of anti-ASP antibodies. ASP antibodies decrease the half-life of ASP, thereby possibly decreasing its effectiveness in patients with ALL. 19, 20 Therefore, an alternative explanation for the ASP data in POG 8602 is that the schedule of administration of ASP markedly decreased the possibility of demonstrating potential efficacy. However, a recent publication by Woo et al 21 demonstrated that hypersensitivity and/or antibodies to ASP did not effect the outcome of patients with ALL. In our study, as in theirs, we immediately switched patients to Erwinia ASP when hypersensitivity to E. coli ASP occurred.
MTX and AraC may be synergistic, additive or antagonistic in their antitumor effects depending upon the schedule of administration and the cell line treated. 22 The overlapping schedule utilized in POG 8602 was based upon the time constraints of IDMTX with leucovorin rescue, and preclinical data indicating that synergy was more likely with longer MTX treatment prior to AraC administration. 22, 23 As predicted from preclinical models, 24 MTX pretreatment significantly increased the ratio of AraC triphosphate to dCTP in bone marrow mononuclear cells at the end of the AraC infusion. However, red cell methotrexate levels in patients treated with MTX plus AraC (regimen C) were significantly lower than in patients treated with MTX alone (regimen A) during intensification. 25 One interpretation of the red blood cell MTX data from POG 8602 is that the overlapping schedule of administration of MTX and AraC resulted in an antagonistic antitumor effect by decreasing MTX uptake. Another interpretation is that treatment with MTX plus AraC was cytotoxic toward reticulocytes and immature red blood cells, which are the cells that accumulate the MTX retained in mature red blood cells. Thus, it is still controversial as to whether or not accumulation of MTX in mature red blood cells can be utilized as a surrogate for tumor uptake of that drug.
This report included patients with standard and high prognosis ALL who had either early pre-B or pre-B phenotype. We previously reported that patients on this study (POG 8602) with pre-B ALL who had the t(1;19)(q23;p13) had an inferior prognosis when compared to pre-B patients without this translocation, and that this translocation rarely occurs in patients with early pre-B ALL. 26 There is now evidence that the survival of children who demonstrate poor prognostic factors is improved by intensifying induction and/or post-induction treatment. Examples of this are more intensive treatment for children with t(1;19) (27, 28) or who demonstrate a slow response to initial therapy. 29 In conclusion, we were unable to show a statistical advantage between asparaginase (regimen B) and cytarabine (regimen C) during the intensification phase of therapy in children with B-lineage acute lymphocytic leukemia. The challenge for future treatment of ALL will be to design the most effective regimens that will improve the survival of children with both standard prognosis and high-risk ALL while decreasing both short-term and long-term side effects. With the establishment of the NCI consensus risk categories for ALL and the stratification of patients with respect to prognostic factors, investigators will be able to compare objectively the efficacy of different treatments within and among cooperative groups.
